Abbott LaboratoriesAbbott Laboratories
Abbott Laboratories

Abbott Laboratories

ABT
Health Care·Health Care Equipment & Supplies

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Illinois; U.S.A
Market cap
No dataNo data
Revenue
$44.3B+5.7% YoY
Net income
$6.5B−51.3% YoY
Free cash flow
$7.4B+16.4% YoY

Market

Listed stock
Tokenized stocks
ABTPriceNYSE
Loading…Loading…1Y

Financial performance

Revenue
$44.3B+5.7% YoY
Operating income
$8.1B+18.0% YoY
Net income
$6.5B−51.3% YoY
Free cash flow
$7.4B+16.4% YoY

Revenue, profit & cash trend

Revenue
Operating income
Net income
Free cash flow
Reference
Revenue: 2021 $43.1B, 2022 $43.7B, 2023 $40.1B, 2024 $42B, 2025 $44.3B. Operating income: 2021 $8.4B, 2022 $8.4B, 2023 $6.5B, 2024 $6.8B, 2025 $8.1B. Net income: 2021 $7.1B, 2022 $6.9B, 2023 $5.7B, 2024 $13.4B, 2025 $6.5B. Free cash flow: 2021 $8.6B, 2022 $7.8B, 2023 $5.1B, 2024 $6.4B, 2025 $7.4B. Reference line: Reference at $0.

Growth & profitability

Revenue growth
5.7%+108 bps YoY
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-12-31 $8.4B, 2022-12-31 $8.4B, 2023-12-31 $6.5B, 2024-12-31 $6.8B, 2025-12-31 $8.1B. Net income: 2021-12-31 $7.1B, 2022-12-31 $6.9B, 2023-12-31 $5.7B, 2024-12-31 $13.4B, 2025-12-31 $6.5B. Free cash flow: 2021-12-31 $8.6B, 2022-12-31 $7.8B, 2023-12-31 $5.1B, 2024-12-31 $6.4B, 2025-12-31 $7.4B

Growth heatmap

2022202320242025CAGR
Revenue
+1.3%
-8.1%
+4.6%
+5.7%
+0.7%
Gross profit
-0.1%
-9.7%
+5.0%
+7.6%
+0.5%
Operating income
-0.7%
-22.5%
+5.4%
+18.0%
-1.1%
Free cash flow
-9.8%
-35.2%
+25.5%
+16.4%
-3.8%

Earnings quality

Operating cash flow
$9.6B+11.8% YoY
Net income
$6.5B−51.3% YoY
Free cash flow
$7.4B+16.4% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 147%, 2024-12-31 64%, 2023-12-31 127%, 2022-12-31 138%, 2021-12-31 149%. Free cash flow: 2025-12-31 113%, 2024-12-31 47%, 2023-12-31 88%, 2022-12-31 113%, 2021-12-31 122%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data